8-K: Monopar Therapeutics Appoints Lavina Talukdar to Board of Directors

Monopar Therapeutics announces the resignation of Michael J. Brown from the Board and the appointment of Lavina Talukdar, Senior Vice President at Moderna Inc., as a new director.

Summary

• Michael J. Brown resigned from Monopar Therapeutics' Board of Directors effective February 19, 2025.
• On February 21, 2025, Lavina Talukdar was appointed to the Board.
• The Corporate Governance and Nominating Committee recommended Ms. Talukdar based on her qualifications and independence.
• Ms. Talukdar was also appointed to the Audit Committee, the Compensation Committee, the Corporate Governance and Nominating Committee, and the Plan Administration Committee.
• She will serve until the next annual meeting of stockholders or until her successor is elected.
• Ms. Talukdar is currently Senior Vice President, Head of Investor Relations at Moderna Inc., a role she has held since April 2019.
• She has over 20 years of experience in investor relations, healthcare investments, and financial strategy.
• Prior to Moderna, she held senior positions at Abu Dhabi Investment Authority, Lord Abbett & Co., MFS Investment Management, and State Street Global Advisors.
• Ms. Talukdar holds a B.S. in Business Administration from SUNY Stony Brook and is a CFA charterholder.
• There are no known arrangements or related party transactions that would affect her appointment.
• Ms. Talukdar will receive standard compensation for non-employee directors.

Sentiment

Score: 7

Explanation: The announcement is generally positive due to the addition of an experienced professional to the board, which could improve investor confidence.

Positives

• The appointment of Lavina Talukdar brings significant experience in investor relations and healthcare investments to the Board.
• Ms. Talukdar's background at Moderna and other investment firms could provide valuable insights for Monopar Therapeutics.
• Her appointment to multiple committees suggests a broad role in shaping the company's strategy and governance.

Future Outlook

The announcement does not contain any specific forward-looking statements regarding the company's financial performance or future projects.

Industry Context

The appointment of an experienced investor relations professional from a major pharmaceutical company like Moderna reflects a focus on enhancing shareholder communication and attracting investment in Monopar Therapeutics.

Management Changes

Related Party Transactions

• There are no disclosed related party transactions between Ms. Talukdar or her family and Monopar Therapeutics.

Stakeholder Impact

• Shareholders may view the appointment of Ms. Talukdar positively, given her experience in investor relations and healthcare investments.
• The appointment could potentially improve the company's access to capital and enhance its corporate governance.

Next Steps

• Ms. Talukdar will serve on the Board until the next annual meeting of stockholders.
• Ms. Talukdar will participate in the Audit Committee, the Compensation Committee, the Corporate Governance and Nominating Committee, and the Plan Administration Committee.

Key Dates

Keywords

Board of Directors, Lavina Talukdar, Monopar Therapeutics, Appointment, Resignation, Corporate Governance, Moderna, Investor Relations